国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2011年
9期
1050-1053
,共4页
范妙玲%刘炼庆%李科伦%邓文全
範妙玲%劉煉慶%李科倫%鄧文全
범묘령%류련경%리과륜%산문전
复发性生殖器疱疹%细胞免疫%治疗
複髮性生殖器皰疹%細胞免疫%治療
복발성생식기포진%세포면역%치료
Recurrent genital herpes%Cell-mediated immunity%Treatment
目的 检测复发性生殖器疱疹患者治疗前、后外周血T淋巴细胞亚群,观察治疗效果,并探讨机体细胞免疫的相关作用机理.方法 复发性生殖器疱疹患者口服泛昔洛韦250mg,每天3次,连服5天,同时给予胸腺五肽1 mg肌注,每天1次,15次为一疗程,共4个疗程.采用流式细胞仪检测52例复发性生殖器疱疹患者治疗前、后T淋巴细胞亚群(CD3+、CD4+、CD8+、CD4+/CD8+),并与40例健康对照组进行比较.结果治疗组与健康对照组相比外周血CD3+、CD4+及CD4+/CD8+下降,CD8+升高,两组间差异有统计学意义(P<0.01).经抗病毒药物与免疫调节剂联合治疗2个月后,外周血CD3+、CD4+及CD4+/CD8+回升,而CD8+下降,治疗前、后差异有统计学意义(P<0.01).治疗前每例年平均发作4.5次,治疗后每例年平均发作1.5次,治疗前、后差异有统计学意义(P<0.05).结论 复发性生殖器疱疹患者存在细胞免疫功能紊乱,抗病毒药物与免疫调节剂联合应用能改善患者的细胞免疫功能紊乱状况,降低生殖器疱疹复发率.
目的 檢測複髮性生殖器皰疹患者治療前、後外週血T淋巴細胞亞群,觀察治療效果,併探討機體細胞免疫的相關作用機理.方法 複髮性生殖器皰疹患者口服汎昔洛韋250mg,每天3次,連服5天,同時給予胸腺五肽1 mg肌註,每天1次,15次為一療程,共4箇療程.採用流式細胞儀檢測52例複髮性生殖器皰疹患者治療前、後T淋巴細胞亞群(CD3+、CD4+、CD8+、CD4+/CD8+),併與40例健康對照組進行比較.結果治療組與健康對照組相比外週血CD3+、CD4+及CD4+/CD8+下降,CD8+升高,兩組間差異有統計學意義(P<0.01).經抗病毒藥物與免疫調節劑聯閤治療2箇月後,外週血CD3+、CD4+及CD4+/CD8+迴升,而CD8+下降,治療前、後差異有統計學意義(P<0.01).治療前每例年平均髮作4.5次,治療後每例年平均髮作1.5次,治療前、後差異有統計學意義(P<0.05).結論 複髮性生殖器皰疹患者存在細胞免疫功能紊亂,抗病毒藥物與免疫調節劑聯閤應用能改善患者的細胞免疫功能紊亂狀況,降低生殖器皰疹複髮率.
목적 검측복발성생식기포진환자치료전、후외주혈T림파세포아군,관찰치료효과,병탐토궤체세포면역적상관작용궤리.방법 복발성생식기포진환자구복범석락위250mg,매천3차,련복5천,동시급여흉선오태1 mg기주,매천1차,15차위일료정,공4개료정.채용류식세포의검측52례복발성생식기포진환자치료전、후T림파세포아군(CD3+、CD4+、CD8+、CD4+/CD8+),병여40례건강대조조진행비교.결과치료조여건강대조조상비외주혈CD3+、CD4+급CD4+/CD8+하강,CD8+승고,량조간차이유통계학의의(P<0.01).경항병독약물여면역조절제연합치료2개월후,외주혈CD3+、CD4+급CD4+/CD8+회승,이CD8+하강,치료전、후차이유통계학의의(P<0.01).치료전매례년평균발작4.5차,치료후매례년평균발작1.5차,치료전、후차이유통계학의의(P<0.05).결론 복발성생식기포진환자존재세포면역공능문란,항병독약물여면역조절제연합응용능개선환자적세포면역공능문란상황,강저생식기포진복발솔.
Objective To observe the therapy efficacy in patients with recurrent genital herpes (RGH)via the detection of the change in peripheral blood T-lymphocyte subpopulation,and to explore the related mechanisms of cell-mediated immunity.Methods 52 patients received a 4-course thempy with oral famciclovir of 250mg,thrice daily for 5 days and an injection of thymopentin of 1 mg once daily for 15days.T-lymphocyte subpopulation(CD3+.CD4+.CD8+,and CD4+/CD8+)was detected by flow cytometry before and after treament.The results were then compared those from the healthy controls.Results As compared with those the control group,CD3+.CD4+.and CD46/CD8+were decreased and CD8+was increased in the treatment group,with a statistical difference between the two groups(P<0.01 ). After a 2-month therapy with antiviral drugs and immunomodulators,CD3+.CD4+ and CD4+/CD8+ elevated and CDs+declined.There was a statistical difference after treatment(P<0.01). Before treatment,each patient had flare-up 4.5 times annually on average,but only 1.5 times after treatment,with a statistical difference(P <0.05). Conclusions Cellular immune dysfunction may occur in patients with RGH.Therapy with antiviral drugs and immunomodulators can improve cell-mediated immunity in the patients,and reduce the recurrence of genital herpes.